Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity

Asia Pacific small molecule contract development and manufacturing organization (CDMO) market will grow by 8.3% annually

Asia Pacific small molecule contract development and manufacturing organization (CDMO) market will grow by 8.3% annually with a total addressable market cap of $234,210.0 million over 2022-2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures. Highlighted with 31 tables and 51 figures, this 110-page report “Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Active Pharmaceutical Ingredients (API) o Branded Drugs o Generic Drugs • Finished Dosage Formulations (FDF) o Oral Solid Drugs o Injectable Drugs o Semi-solid or Liquid Drugs o Other FDFs Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Preclinical Use • Clinical Use o Phase I o Phase II o Phase III o Phase IV • Commercial Use By Customer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Pharmaceutical Firms • Biotechnology Firms

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Respiratory Disorders • Metabolic Diseases • Other Therapeutic Areas Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product Type, Service Type and Therapeutic Area over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Boehringer Ingelheim Cambrex Corporation Catalent Cipla Covance Inc. Lonza Group Ltd. Medley Pharmaceuticals NatcoPharma Patheon (Thermo Fisher Scientific, Inc.) Piramal Pharma Solutions RedHillBiopharma Siegfried Holding AG STA Pharmaceutical Sun Pharmaceutical Teva (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Table of Contents

  • 1 Introduction 7
  • 1.1 Industry Definition and Research Scope 7
  • 1.1.1 Industry Definition 7
  • 1.1.2 Research Scope 8
  • 1.2 Research Methodology 11
  • 1.2.1 Overview of Market Research Methodology 11
  • 1.2.2 Market Assumption 12
  • 1.2.3 Secondary Data 12
  • 1.2.4 Primary Data 12
  • 1.2.5 Data Filtration and Model Design 13
  • 1.2.6 Market Size/Share Estimation 14
  • 1.2.7 Research Limitations 15
  • 1.3 Executive Summary 16
  • 2 Market Overview and Dynamics 19
  • 2.1 Market Size and Forecast 19
  • 2.1.1 Impact of COVID-19 on World Economy 20
  • 2.1.2 Impact of COVID-19 on the Market 22
  • 2.2 Major Growth Drivers 24
  • 2.3 Market Restraints and Challenges 28
  • 2.4 Emerging Opportunities and Market Trends 31
  • 2.5 Porter’s Fiver Forces Analysis 35
  • 3 Segmentation of Asia Pacific Market by Product Type 39
  • 3.1 Market Overview by Product Type 39
  • 3.2 Active Pharmaceutical Ingredients (API) 41
  • 3.2.1 Branded Drugs 42
  • 3.2.2 Generic Drugs 43
  • 3.3 Finished Dosage Formulations (FDF) 44
  • 3.3.1 Oral Solid Drugs 46
  • 3.3.2 Injectable Drugs 47
  • 3.3.3 Semi-solid or Liquid Drugs 48
  • 3.3.4 Other FDFs 49
  • 4 Segmentation of Asia Pacific Market by Service Type 50
  • 4.1 Market Overview by Service Type 50
  • 4.2 Preclinical Use 52
  • 4.3 Clinical Use 53
  • 4.3.1 Phase I 55
  • 4.3.2 Phase II 56
  • 4.3.3 Phase III 57
  • 4.3.4 Phase IV 58
  • 4.4 Commercial Use 59
  • 5 Segmentation of Asia Pacific Market by Customer Type 60
  • 5.1 Market Overview by Customer Type 60
  • 5.2 Pharmaceutical Firms 62
  • 5.3 Biotechnology Firms 63
  • 6 Segmentation of Asia Pacific Market by Therapeutic Area 64
  • 6.1 Market Overview by Therapeutic Area 64
  • 6.2 Infectious Diseases 66
  • 6.3 Oncology 67
  • 6.4 Ophthalmology 68
  • 6.5 Cardiovascular Disorders 69
  • 6.6 Central Nervous System 70
  • 6.7 Respiratory Disorders 71
  • 6.8 Metabolic Diseases 72
  • 6.9 Other Therapeutic Areas 73
  • 7 Asia-Pacific Market 2021-2031 by Country 74
  • 7.1 Overview of Asia-Pacific Market 74
  • 7.2 Japan 77
  • 7.3 China 80
  • 7.4 Australia 82
  • 7.5 India 84
  • 7.6 South Korea 86
  • 7.7 Rest of APAC Region 88
  • 8 Competitive Landscape 90
  • 8.1 Overview of Key Vendors 90
  • 8.2 New Product Launch, Partnership, Investment, and M&A 93
  • 8.3 Company Profiles 94
  • Boehringer Ingelheim 94
  • Cambrex Corporation 96
  • Catalent 97
  • Cipla 98
  • Covance Inc. 99
  • Lonza Group Ltd. 100
  • Medley Pharmaceuticals 101
  • NatcoPharma 102
  • Patheon (Thermo Fisher Scientific, Inc.) 103
  • Piramal Pharma Solutions 104
  • RedHillBiopharma 105
  • Siegfried Holding AG 106
  • STA Pharmaceutical 107
  • Sun Pharmaceutical 108
  • Teva 109
  • RELATED REPORTS 110

List of Figures:

Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. Asia Pacific Small Molecule CDMO Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Small Molecule CDMO Market 24
Figure 7. Primary Restraints and Impact Factors of Asia Pacific Small Molecule CDMO Market 28
Figure 8. Investment Opportunity Analysis 32
Figure 9. Porter’s Fiver Forces Analysis of Asia Pacific Small Molecule CDMO Market 35
Figure 10. Breakdown of Asia Pacific Small Molecule CDMO Market by Product Type, 2021-2031, % of Revenue 40
Figure 11. Asia Pacific Addressable Market Cap in 2022-2031 by Product Type, Value ($ mn) and Share (%) 40
Figure 12. Asia Pacific Small Molecule CDMO Market by Product Type: Active Pharmaceutical Ingredients (API), 2021-2031, $ mn 41
Figure 13. Asia Pacific Small Molecule CDMO Market by API: Branded Drugs, 2021-2031, $ mn 42
Figure 14. Asia Pacific Small Molecule CDMO Market by API: Generic Drugs, 2021-2031, $ mn 43
Figure 15. Asia Pacific Small Molecule CDMO Market by Product Type: Finished Dosage Formulations (FDF), 2021-2031, $ mn 44
Figure 16. Asia Pacific Small Molecule CDMO Market by FDF: Oral Solid Drugs, 2021-2031, $ mn 46
Figure 17. Asia Pacific Small Molecule CDMO Market by FDF: Injectable Drugs, 2021-2031, $ mn 47
Figure 18. Asia Pacific Small Molecule CDMO Market by FDF: Semi-solid or Liquid Drugs, 2021-2031, $ mn 48
Figure 19. Asia Pacific Small Molecule CDMO Market by FDF: Other FDFs, 2021-2031, $ mn 49
Figure 20. Breakdown of Asia Pacific Small Molecule CDMO Market by Service Type, 2021-2031, % of Sales Revenue 51
Figure 21. Asia Pacific Addressable Market Cap in 2022-2031 by Service Type, Value ($ mn) and Share (%) 51
Figure 22. Asia Pacific Small Molecule CDMO Market by Service Type: Preclinical Use, 2021-2031, $ mn 52
Figure 23. Asia Pacific Small Molecule CDMO Market by Service Type: Clinical Use, 2021-2031, $ mn 53
Figure 24. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase I, 2021-2031, $ mn 55
Figure 25. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase II, 2021-2031, $ mn 56
Figure 26. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase III, 2021-2031, $ mn 57
Figure 27. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase IV, 2021-2031, $ mn 58
Figure 28. Asia Pacific Small Molecule CDMO Market by Service Type: Commercial Use, 2021-2031, $ mn 59
Figure 29. Breakdown of Asia Pacific Small Molecule CDMO Market by Customer Type, 2021-2031, % of Sales Revenue 61
Figure 30. Asia Pacific Addressable Market Cap in 2022-2031 by Customer Type, Value ($ mn) and Share (%) 61
Figure 31. Asia Pacific Small Molecule CDMO Market by Customer Type: Pharmaceutical Firms, 2021-2031, $ mn 62
Figure 32. Asia Pacific Small Molecule CDMO Market by Customer Type: Biotechnology Firms, 2021-2031, $ mn 63
Figure 33. Breakdown of Asia Pacific Small Molecule CDMO Market by Therapeutic Area, 2021-2031, % of Revenue 65
Figure 34. Asia Pacific Addressable Market Cap in 2022-2031 by Therapeutic Area, Value ($ mn) and Share (%) 65
Figure 35. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Infectious Diseases, 2021-2031, $ mn 66
Figure 36. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Oncology, 2021-2031, $ mn 67
Figure 37. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Ophthalmology, 2021-2031, $ mn 68
Figure 38. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Cardiovascular Disorders, 2021-2031, $ mn 69
Figure 39. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Central Nervous System, 2021-2031, $ mn 70
Figure 40. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Respiratory Disorders, 2021-2031, $ mn 71
Figure 41. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Metabolic Diseases, 2021-2031, $ mn 72
Figure 42. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Other Therapeutic Areas, 2021-2031, $ mn 73
Figure 43. Breakdown of APAC Small Molecule CDMO Market by Country, 2021 and 2031, % of Revenue 75
Figure 44. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 76
Figure 45. Small Molecule CDMO Market in Japan, 2021-2031, $ mn 78
Figure 46. Small Molecule CDMO Market in China, 2021-2031, $ mn 80
Figure 47. Small Molecule CDMO Market in Australia, 2021-2031, $ mn 82
Figure 48. Small Molecule CDMO Market in India, 2021-2031, $ mn 84
Figure 49. Small Molecule CDMO Market in South Korea, 2021-2031, $ mn 86
Figure 50. Small Molecule CDMO Market in Rest of APAC, 2021-2031, $ mn 88
Figure 51. Growth Stage of Asia Pacific Small Molecule CDMO Industry over the Forecast Period 90

List of Tables:

Table 1. Snapshot of Asia Pacific Small Molecule CDMO Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 21
Table 3. Worldwide Total Number of Registered Clinical Trials 27
Table 4. Main Product Trends and Market Opportunities in Asia Pacific Small Molecule CDMO Market 31
Table 5. Asia Pacific Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 39
Table 6. Asia Pacific Small Molecule CDMO Market: API by Type, 2021-2031, $ mn 41
Table 7. Asia Pacific Small Molecule CDMO Market: FDF by Type, 2021-2031, $ mn 45
Table 8. Asia Pacific Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 50
Table 9. Asia Pacific Small Molecule CDMO Market: Clinical Use by Type, 2021-2031, $ mn 54
Table 10. Asia Pacific Small Molecule CDMO Market by Customer Type, 2021-2031, $ mn 60
Table 11. Asia Pacific Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 64
Table 12. APAC Small Molecule CDMO Market by Country, 2021-2031, $ mn 75
Table 13. Japan Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 79
Table 14. Japan Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 79
Table 15. Japan Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 79
Table 16. China Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 81
Table 17. China Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 81
Table 18. China Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 81
Table 19. Australia Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 83
Table 20. Australia Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 83
Table 21. Australia Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 83
Table 22. India Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 85
Table 23. India Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 85
Table 24. India Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 85
Table 25. South Korea Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 87
Table 26. South Korea Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 87
Table 27. South Korea Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 87
Table 28. Small Molecule CDMO Market in Rest of APAC by Country/Region, 2021-2031, $ mn 89
Table 29. Boehringer Ingelheim: Company Snapshot 94
Table 30. Boehringer Ingelheim: Business Segmentation 95
Table 31. Boehringer Ingelheim: Product Portfolio 95
Logo

Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity

Contact usWe are friendly and approachable, give us a call.